Skip to Content

Alan Rapraeger

From Human Oncology

Jump to: navigation, search


Rapraeger portrait.jpg

Alan Rapraeger

PROFESSOR

CONTACT INFORMATION

    Phone: (608) 262-7577
    E-mail:

    Mailing Address:
    3053 Wi Institute Medical Research
    1111 Highland Ave
    Madison, WI 53705

Rapraeger Lab Page

Rapraeger Lab

Education

1972 B.S., Biology, University of Oregon, Eugene

1978 Ph.D., Zoology, University of California-Berkeley

1979-80 Postdoctoral Scholar, Dept. of Biological Sciences, Hopkins Marine Station, Stanford University

1981-85 Postdoctoral Scholar, Developmental Biology, Dept. of Pediatrics, Stanford University, CA.

Positions Held

1985-91 Assistant Professor, Department of Pathology, University of Wisconsin-Madison

1990-present Member, Comprehensive Cancer Center, University of Wisconsin-Madison

1991-1996 Associate Professor, Department of Pathology , University of Wisconsin-Madison

1993-1996 Director, Graduate Program in Developmental Biology, University of Wisconsin

1996-present Professor, Department of Pathology, University of Wisconsin-Madison

1997-2001 Program Leader, Cell Signaling and Growth Control, Comprehensive Cancer Center, University of Wisconsin-Madison

2003-present Vice Chair for Education, Department of Pathology, University of Wisconsin-Madison

Leadership Roles/Advisory Panels

NSF Developmental Biology Review Panel (1989-1993)

Associate Editor, Journal of Cell Science (1991 - 94)

Member, Maternal and Child Health Research Committee, National Institutes of Health, (1994)

Ad hoc member, NIH Pathobiochemistry Study Section (1995, 1996)

Member, NIH Special Review Committee, National Heart, Lung and Blood Institute (1995)

Member, NIH Special Review Committee, National Institute of Diabetes and Digestive and Kidney Disorders (1995)

Advisory Committee, 1996 Proteoglycan Gordon Conference

American Cancer Society Review Panel (1996)

NCI Program Project Site Visit Committee, Mayo Clinic, 1997

Member, NIH Pathobiochemistry Study Section, 1997-2001

NCI Cancer Center Site Visit Committee, Burnham Institute, 1998

Ad hoc member, NCI Initial Review Group, subcommittee A, 1998

NICHHD, Program Project Site Visit Committee, Burnham Institute, 1999

Member, NCI site visit review panel, University of Arkansas for Medical Sciences, 1999

Ad hoc member, NICHHD Initial Review Group, Maternal and Child Health Research Subcommittee, 1999

Advisory Board, Program Project Grant on Regulation of Growth Factor Signaling (A. Lander, PI), Univ. Calif. Irvine. 2001

Extenal Advisory Committee, program on Studies of Monoclonal Gammopathies, Mayo Clinic, 2001-present

NCI Special Emphasis Panel, ZCA1 SRRB-D (2001)

Organizing committee, 2002 Gordon Conference on Proteoglycans, 2001-2002

Editorial Board, Journal of Biological Chemistry, 2002-2007

NCI program project site visit panel, Emory University, 2002

Ad hoc member, NIH Pathobiochemistry study section, June 2002

Organizing Committee, 2004 Annual Meeting, Amercian Society for Matrix Biology

Vice-Chair, Proteoglycan Gordon Conference, 2004

Advisory Council, American Society for Matrix Biology, 2005-2008

Member, NIH Intercellular Interactions (ICI) Special Emphasis Panel, 2005

Chair, Proteoglycan Gordon Conference, 2006

Chair, NIH Intercellular Interactions (ICI) study section, 2006-2008

Advisory Board, International Symposium on Extracellular Glycomatrix in Health and Disease, Awaji, Japan 2006

Research

Awards

Recent Publications

Narendra Thapa, Xiaojun Tan, Suyong Choi, Paul F Lambert, Alan C Rapraeger, Richard A Anderson
The Hidden Conundrum of Phosphoinositide Signaling in Cancer.
Trends Cancer: 2016, 2(7);378-390
[PubMed:27819060]

Ralph D Sanderson, Michael Elkin, Alan C Rapraeger, Neta Ilan, Israel Vlodavsky
Heparanase regulation of cancer, autophagy and inflammation: new mechanisms and targets for therapy.
FEBS J.: 2017, 284(1);42-55
[PubMed:27758044]

DeannaLee M Beauvais, Oisun Jung, Yang Yang, Ralph D Sanderson, Alan C Rapraeger
Syndecan-1 (CD138) Suppresses Apoptosis in Multiple Myeloma by Activating IGF1 Receptor: Prevention by SynstatinIGF1R Inhibits Tumor Growth.
Cancer Res.: 2016, 76(17);4981-93
[PubMed:27364558]

O Jung, V Trapp-Stamborski, A Purushothaman, H Jin, H Wang, R D Sanderson, A C Rapraeger
Heparanase-induced shedding of syndecan-1/CD138 in myeloma and endothelial cells activates VEGFR2 and an invasive phenotype: prevention by novel synstatins.
Oncogenesis: 2016, 5();e202
[PubMed:26926788]

Xiaojun Tan, Paul F Lambert, Alan C Rapraeger, Richard A Anderson
Stress-Induced EGFR Trafficking: Mechanisms, Functions, and Therapeutic Implications.
Trends Cell Biol.: 2016, 26(5);352-66
[PubMed:26827089]